Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
AstraZeneca
Colorcon
Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

KEPIVANCE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Tradename: KEPIVANCE
Recent Clinical Trials for KEPIVANCE

Identify potential brand extensions & biosimilar entrants

SponsorPhase
City of Hope Medical CenterPhase 1
Spectrum Pharmaceuticals, IncPhase 1/Phase 2
AstraZenecaPhase 1/Phase 2

See all KEPIVANCE clinical trials

Pharmacology for KEPIVANCE

Company Disclosures: US Patents for KEPIVANCE

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Chiron Corporation (Emeryville, CA) 2039-03-29 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Amgen Inc. (Thousand Oaks, CA) 2015-09-29 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial Amgen Inc. (Thousand Oaks, CA) 2015-10-20 RX company
Biovitrum Ab KEPIVANCE palifermin INJECTABLE; INJECTION 125103 001 2004-12-15   Start Trial The United States as represented by the Department of Health and Human (N/A) (Washington, DC) 2019-07-16 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for KEPIVANCE

These patents were identified by searching patent claims

Supplementary Protection Certificates for KEPIVANCE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2006 00004 Denmark   Start Trial PRODUCT NAME: PALIFERMIN
122006000021 Germany   Start Trial PRODUCT NAME: PALIFERMIN; REGISTRATION NO/DATE: EU/1/05/314/001 20051025
C00706563/01 Switzerland   Start Trial PRODUCT NAME: PALIFERMIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57334 11.09.2006
06C0016 France   Start Trial PRODUCT NAME: PALIFERMINE; REGISTRATION NO/DATE IN FRANCE: EU/1/05/314/001 DU 20051025; REGISTRATION NO/DATE AT EEC: EU/1/05/314/001 DU 20051025
SZ 4/2006 Austria   Start Trial PRODUCT NAME: PALIFERMIN
122006000005 Germany   Start Trial PRODUCT NAME: PALIFERMIN IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/05/314/001 20051025
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Harvard Business School
Boehringer Ingelheim
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.